BNET Industries
Emergent Biosolutions (EBS) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $182.9M
- Profit
- Dec 31 2007
- $22.9M
- Market Cap
- Oct 09 2008
- $369.3M
Latest News and Analysis
Emergent BioSolutions: Surprising Value Play
Saj Karsan submits: Emergent BioSolutions Inc. (NYSE: EBS) does not have the makings of an ideal value stock. Assessing this small pharmaceutical company, value investors would tend to worry about the risks of being too reliant on only a few drugs. We discussed here how the diversity of large pharma...
Emergent BioSolutions Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer Session Operator Thank you. Operator instructions Your first question comes from the line of Eric Schmidt representing Cowen & Company. Please proceed. Eric Schmidt – Cowen & Company Hi, good morning. Thanks for taking my call. Don, in terms of the operating cash used in the quarter, are...
Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
* Study designed to confirm safety and immunogenicity of vaccine manufactured at the large-scale commercial facility planned for launch
Emergent BioSolutions and the European Corporate Security Association Sponsor a Conference on Bioterrorism
Attendees Include Key Officials from the European Union, International and Diplomatic Institutions
Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Jefferies and Company 2nd Annual Healthcare Conference scheduled for Wednesday June 25, 2008 at 3:45 pm Eastern. A member of the company's senior management team will provide a corporate overview, including...
Rockville-based Emergent BioSolutions buys Protein Sciences
Emergent BioSolutions is purchasing Protein Sciences Corp., which makes the next-generation flu vaccine the government has put on the fast-track approval process, The Washington Post reported. Rockville- based Emergent could pay more than $75 million for Protein Sciences, based in Meriden, Conn., the newspaper said in its Tuesday editions. According...
Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok®, and Related Novel Platform Technology
* FluBlok BLA granted fast track status and priority review by FDA; would be the first licensed recombinant hemagglutinin cell culture influenza vaccine
Emergent BioSolutions Inc. Q1 2008 Earnings Call Transcript
Question-and-Answer Session Operator Operator instructions And your first question comes from the line of Richard Smith with JP Morgan. Please proceed. Richard Smith – JP Morgan Yes, good morning everyone. Fuad El-Hibri Good morning. Don Elsey Good morning Rich. Richard Smith – JP Morgan Good morning. Just a quick...
Emergent's Vaccine Play: Biotech Can Flip-Flop, Too
For sudden twists of fate, abrupt collapses and the occasional stunning revival, it's hard to beat the biotech industry. Yesterday, for instance, the all-but-dead biotech VaxGen agreed to sell off its ailing anthrax vaccine to its East Coast rival Emergent BioSolutions --a company that spent much of this decade trying...
Emergent Biosolutions Inc. Q4 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you, ladies and gentlemen, if you wish to ask a question, press star one on your touchtone telephone. If your question has been answered or you wish to withdraw your question, press star two. Questions will be taken in the order received. ...
Emergent BioSolutions Reports Financial Results for 2007
-- Record revenues of $182.9 million
Emergent BioSolutions to Present at Upcoming Investor Conferences
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS), announced today that company management will be presenting at the following two investor conferences over the next thirty day period.
Emergent BioSolutions to Lead a United States Delegation to the United States - India Business Council Health Summit in India
Summit Will Focus on Improving the Quality of Healthcare in India
Emergent BioSolutions Announces Update on Department of Defense Procurement Strategy For BioThrax®
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has been advised that the U.S. Department of Defense DoD intends to pursue a collaborative arrangement with the U.S. Department of Health and Human Services HHS to facilitate the use by DoD of stockpiled doses of BioThrax([R]) Anthrax Vaccine Adsorbed...
Emergent Biosolutions Q3 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of Gene Mack with HSBC Securities. Please proceed. Gene Mack - HSBC Securities Thanks. Fuad, I wonder if you could just give a little more detail on. I mean I guess if I do the back calculation,...
Emergent BioSolutions Reports Financial Results for Third Quarter 2007
-- Raises full year 2007 revenue guidance to reflect annual growth of 16 to 18 percent
Emergent BioSolutions to Present at November Investor Conferences
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS), announced today that company management will be presenting at two investor conferences during the month of November. The November conferences are:
Emergent BioSolutions to Release Third Quarter 2007 Financial Results on November 2, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS), announced today that it will report financial results for the third quarter 2007 on Friday, November 2, 2007, before market open.
Emergent BioSolutions Announces Dr. Stephen Lockhart Joins Company to Lead Commercial Product Development Subsidiary
Dr. Lockhart Brings Top-Tier Pharma Leadership to Development of Company's Commercial Product Portfolio
Emergent BioSolutions' Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study
Vaccine Well Tolerated and Immunogenic in Double-Blind, Placebo-Controlled Study in Pediatric Population
- Next »
- page 1 of 3
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1998
- CEO: Mr. Fuad El-Hibri
Emergent BioSolutions is a biopharmaceutical company that develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. At Dec 31 2007, Co. manufactured and marketed BioThrax®, a vaccine for the prevention of anthrax infection. Co. operates in two business segments: biodefense, which focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare; and commercial, which focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.
Key Competitors
Emergent Biosolutions Company Info
Board of Directors
Mr. Fuad El-Hibri
Chairman
Dr. Zsolt Harsanyi Ph.D.
Dr. Louis W. Sullivan M.D
Mr. Joseph M. Allbaugh
Dr. Sue Bailey M.D.
Mr. Jerome M. Hauer
Mr. Ronald B. Richard
Dr. Shahzad Malik
Contact Information
2273 Research Blvd.
Suite 400
Rockville, MD
http://www.emergentbiosolutions.com
301 795-1800
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
